Objectives. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite clinical tool combining subjective and objective measures. Using data from the randomized double-blind Ankylosing Spondylitis Study Comparing Enbrel with Sulfasalazine Dosed Weekly (ASCEND) trial, we tested ASDAS validity and assessed its capacity to discriminate between treatment effects and change-from-baseline improvements.
Introduction
AS, the most typical form of SpA, is characterized by pain and stiffness in the spine and SI and peripheral joints, with additional potential effects on the eyes, heart, lungs and bowel [1] . This chronic inflammatory disease frequently presents in early adulthood and may seriously impair affected patients' quality of life (QoL) and working ability [2, 3] . SSZ is commonly used for the treatment of AS, although it may only be suitable for patients with peripheral articular manifestations [4, 5] . Etanercept is a fully human TNF soluble receptor that has demonstrated short-and long-term efficacy across a range of objective and subjective outcome measures in patients with AS [69] , including improvements in patient health-related QoL [2] .
Outcome assessment in AS is based mainly on subjective endpoints (e.g. validated patient-reported questionnaires). However, in recent years it became obvious that more objective measures such as CRP are important to detect improvement and discriminate between treatment effects. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite measure of disease activity that was recently developed and endorsed by the Assessment of Spondyloarthritis International Society (ASAS) [10] . ASDAS is a combination of subjective measures and an acute-phase reactant. ASDAS can be used as a continuous measure, and cutoffs for response and disease activity states have been defined [10, 11] .
The primary objective of this post hoc analysis was to test the validity of ASDAS relative to other standard measures of efficacy. Randomized controlled data from the Ankylosing Spondylitis Study Comparing Enbrel with Sulfasalazine Dosed Weekly (ASCEND) trial was used for this purpose [12] . In addition, we tested the capacity of ASDAS against other assessments to discriminate between the treatment effects of SSZ and etanercept and to detect sensitivity in change-from-baseline improvements for each treatment.
Methods
The full methodology of the randomized, doubleblind, multicentre, active-comparator ASCEND trial (NCT00247962) has been published previously [12] . Briefly, consenting patients enrolled in the ASCEND trial were 518 years of age and had a diagnosis of AS based on the modified New York criteria [12, 13] . After a screening period of up to 4 weeks, patients were randomly assigned in a 2:1 ratio to receive either etanercept 50 mg once weekly or SSZ titrated to a target dose of 3.0 g daily in a divided dose for 16 weeks. The ASCEND trial was conducted in accordance with the ethical principles of the Declaration of Helsinki.
Disease activity assessments
Thirty-one continuous and 11 dichotomous endpoints were assessed in the ASCEND trial. Objective measures and composites of objective and subjective measures of AS disease activity included ASDAS (analysed post hoc); BASMI (including cervical rotation, intermalleolar distance, lateral flexion, modified Schober's test and tragus-to-wall distance); chest expansion; occiput-to-wall distance; CRP; and swollen and tender joint counts. Subjective measures included ASAS20; Ankylosing Spondylitis Quality of Life (ASQoL); BASDAI; BASFI; patient global assessment (PGA) of disease activity and of peripheral joint arthritis; physician global assessment of disease activity and of peripheral joint arthritis; back pain and nocturnal back pain; visual analogue scale (VAS) and derived EuroQoL (EQ-5D); Hospital and Depression Scale total, anxiety and depression scores; stiffness (average of duration and level of stiffness), duration of stiffness and level of stiffness; and shortform 36 (SF-36) mental component summary (MCS) and physical component summary (PCS). All assessments were conducted at baseline and after 16 weeks of randomized treatment.
ASDAS was calculated as 0.121 Â total back pain + 0.110 Â PGA of disease activity + 0.073 Â BASDAI question 3 (pain and swelling from peripheral arthritis) + 0.058 Â BASDAI question 6 (duration of morning stiffness) + 0.579 Â natural log of (CRP + 1) [10] . An ASDAS of < 1.3 defines inactive disease; 1.3 4 ASDAS <2.1, moderate disease activity; 2.1 4 ASDAS 43.5, high disease activity; and ASDAS >3.5, very high disease activity [11] . An improvement of 51.1 units is a clinically important improvement, and an improvement of 52 units is a major response [11] .
BASDAI was defined as having a score of 010 (0À10 cm VAS) in each of the following domains: fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness (both qualitative and quantitative) [14] .
ASAS partial remission was defined as having a score of <2 (0À10 cm scale) in each of the following domains: VAS PGA, average VAS for total and nocturnal pain, BASFI and average of BASDAI questions on morning stiffness (length and level of morning stiffness).
ASAS20 was defined as an improvement of 520% and absolute improvement of 51 unit on a 010 scale in three or more of the following four domains (and an absence of 520% deterioration in the potential remaining domain): PGA (by VAS global assessment); pain assessment (the average of VAS total and nocturnal pain scores); function (represented by BASFI); and inflammation (the average of the BASDAI's last two VAS concerning morning stiffness intensity and duration).
Statistics
All analyses were performed on the modified intent-totreat population (defined as all randomized patients who received 51 dose of study drug and provided data at baseline and week 16), which automatically defined the observed case approach.
Regarding the primary objective, ASDAS validation, descriptive statistics (mean and associated 95% CI) were presented for ASDAS scores for patients attaining and not attaining ASAS partial remission at week 16. The same procedure was completed for ASDAS change from baseline among patients attaining and not attaining ASAS20. A two-sample t-test was used to detect statistically significant differences between ASDAS means for patients with and without ASAS partial remission and ASDAS mean change from baseline in patients with and without ASAS20.
ASDAS mean changes (95% CIs) over 16 weeks were calculated, with treatment differences being tested in an analysis of covariance (ANCOVA) model with treatment, geographic region and ASDAS baseline as predictors.
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Countries were pooled into the geographic regions of Asia Pacific, Latin America, Eastern Europe and Western Europe. Mean changes (95% CIs) from baseline in BASDAI scores at week 16 were calculated in the same way.
Regarding sensitivity of responses to treatment, two analyses were performed for each continuous endpoint. The first analysis, performed separately for each treatment, calculated the adjusted standardized mean of improvement from baseline (mean/S.D.) from an ANCOVA model adjusted for the baseline endpoint and pooled geographical area. For each continuous endpoint, the second analysis calculated the adjusted treatment differences of improvement from baseline, which were derived from an ANCOVA of week 16 improvement from baseline, with treatment effect, baseline endpoint and geographic region in the model. Adjusted effect size and its 95% CI were derived by taking the adjusted treatment difference and its 95% CI and dividing them by the ANCOVA model-based S.D. estimate. This procedure was repeated on subgroups of patients stratified by (i) normal (<9 mg/l) or high (59 mg/l) CRP level at baseline for 500 patients and normal (44 mg/l) and high (>4 mg/l) CRP level at baseline for 25 patients (normal value ranges varied between two different laboratories); (ii) presence or absence of peripheral joint arthritis at baseline (defined as either swollen joints 51 or tender joints 51); and (iii) high (52.1 ASDAS 43.5) or very high ASDAS (ASDAS >3.5) at baseline. In the second subgroup analysis listed above, a positive personal history of peripheral joint arthritis was used for 10 patients who had no baseline joint assessments.
For each dichotomous endpoint, the adjusted treatment difference was estimated from a generalized linear model with geographic region as a predictor. Treatment difference was the difference between the proportion of etanercept patients who achieved the endpoint and the proportion of SSZ patients who achieved the endpoint. The adjusted mean effect size and its 95% CI were derived by taking the adjusted mean treatment difference and its 95% CI and dividing by the model-based S.D.
Results

Patients
The primary results of the ASCEND trial have been published previously [12] . Table 1 shows that after randomization, patient demographics and disease characteristics were similar between treatment groups at baseline.
ASDAS validation
Across the study population at week 16, 152/519 patients (29%) achieved ASAS partial remission and 369/517 patients (71%) had an ASAS20 response. Within the etanercept and SSZ groups, respectively, 123/352 patients (35%) and 29/167 patients (17%) achieved ASAS partial remission, and 275/350 patients (79%) and 94/167 patients (56%) had an ASAS20 response.
Means for ASDAS were less than half in patients with partial remission compared with patients without partial remission across the entire study population (1.2 vs 2.6) and within the etanercept (1.2 vs 2.4) and SSZ groups (1.4 vs 3.0; all P < 0.0001). Similarly, patients who achieved ASAS20 had far greater mean changes from baseline in ASDAS than those who did not achieve ASAS20 in the study overall (À1.8 vs À0.3; P < 0.0001) and in the two treatment groups (etanercept, À1.9 vs À0.6; SSZ, À1.5 vs À0.1; both P < 0.0001).
Further analysis revealed that both treatments were associated with improvements in mean ASDAS with respect to baseline (Fig. 1) ; however, based on the ANCOVA model, improvement in the etanercept group was markedly greater than that in the SSZ group at week 2 (ASDAS percentage change from baseline, À32.9 vs À9.2%) and at each scheduled study visit thereafter (week 4, À36.2 vs À16.7%; week 8, À41.9 vs À20.3%; week 12, À44.5 vs À22.2%; week 16, À45.6 vs À23.8%; all P < 0.001).
Responses Fig. 2 illustrates week 16 adjusted standardized means of improvement from baseline for all continuous endpoints by treatment group. On every measure, both interventions were associated with improvements. The rank order of endpoints by degree of sensitivity in improvement was similar in the two groups. The disease activity physician global assessment, ASDAS, level of stiffness, stiffness (average of duration and level of stiffness) and the BASDAI were among the best at showing the adjusted standardized mean improvement from baseline after treatment with etanercept and with SSZ.
The adjusted treatment differences and effect sizes of improvement from baseline between treatment groups for all continuous and dichotomous endpoints are shown in descending order based on their treatment-effect size (Fig. 3) . Positive values for adjusted treatment differences were obtained across all endpoints at week 16, indicating that patients receiving etanercept had improved clinical status relative to counterparts receiving SSZ. Regarding continuous endpoints, the ASDAS, CRP (an objective measure) and nocturnal back pain (a subjective measure) were among the best in discriminating between etanercept and SSZ treatment effects. Subjective outcome measures such as stiffness, back pain, PGA disease activity and disease activity physician global assessment showed a somewhat lower discriminatory capacity than ASDAS and CRP. Among dichotomous endpoints, ASDAS improvement 51.1 and 52.0 showed similar discriminatory capacity between treatments as ASAS20 and ASAS40, whereas ASDAS inactive disease showed similar discrimination as ASAS partial remission. In comparison, most of the other measures consistently ranked low in their capacity to discriminate between treatment effects.
Subgroup analysis
Most endpoints in the baseline CRP subgroups had the following sample sizes: normal level, n ffi 150 for etanercept and n ffi 70 for SSZ; high level, n ffi 200 for etanercept and n ffi 100 for SSZ. Similarly, most endpoints in the baseline peripheral joint arthritis subgroups had the following sample sizes: no peripheral joint arthritis, n ffi 100 for etanercept and n ffi 40 for SSZ; peripheral joint arthritis, n ffi 250 for etanercept and n ffi 135 for SSZ. Most endpoints in the disease activity subgroups had the following sample sizes: high disease activity (52.1 ASDAS 43.5), n ffi 150 for etanercept and n ffi 70 for SSZ; very high disease activity (ASDAS >3.5), n ffi 200 for etanercept and n ffi 100 for SSZ. Subgroup analyses could not be performed on the inactive/moderate disease activity (ASDAS <2.1) subgroup because only a small number of patients in the etanercept group and no patients in the SSZ group met this criteria at baseline.
As the ASDAS features the CRP level and an assessment of peripheral joint involvement, a clinically relevant question was to address if the measure performed differently in patients with a normal vs an elevated CRP and in patients with the absence or presence of peripheral arthritis at baseline. Regarding the capacity to gage the degree of improvement from baseline in each treatment group, ASDAS and BASDAI were among the top six Any between-treatment differences were detected using one-way ANOVA with treatment as factor for continuous parameters and 2 tests for categorical parameters.
a Only patients who received stable NSAIDs/corticosteroids within 2 weeks of baseline were included.
b From 2 weeks before baseline. Patients who had an intolerance or lack of efficacy to SSZ were not eligible for inclusion in the study. 
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ASDAS validation in the ASCEND trial ranked tools among patients with a high and normal baseline CRP level (along with disease activity physician global assessment, level of stiffness, average of level and duration of stiffness and peripheral joint arthritis physician global assessment). The discriminatory capacity of ASDAS relative to BASDAI with respect to CRP level is shown in Fig. 4 . Subgroup analysis revealed that etanercept and SSZ were associated with mean improvements from baseline at week 16 for ASDAS and BASDAI regardless of baseline CRP status; however, the mean change from baseline improvement in ASDAS and BASDAI was greatest in patients with a high CRP level at baseline. Regarding the adjusted effect sizes of improvement from baseline between etanercept and SSZ, numerous measures (from peripheral joint question to BASFI) including ASDAS had similar discriminatory capacity in patients with a normal CRP level (Fig. 5A) . In patients with an elevated CRP level at baseline, ASDAS and CRP had high discriminatory capacity (adjusted effect size, 1.16 and 1.01, respectively), with BASDAI ranking below these endpoints (adjusted effect size, 0.63) (Fig. 5B) . Fig. 5C shows that in patients without peripheral joint arthritis at baseline ASDAS had one of the highest discriminatory capacities (adjusted effect size 0.84). In patients with peripheral joint arthritis at baseline (defined as either swollen joints 51 or tender joints 5 1), CRP (adjusted effect sizes 0.94) and ASDAS (adjusted effect size 0.92) performed the best. PGA and physician global assessment of peripheral joint arthritis (adjusted effect sizes 0.59 and 0.51, respectively) and tender and swollen joint count (adjusted effect sizes 0.23 and 0.20, respectively) all ranked far lower than the ASDAS in patients with peripheral joint arthritis at baseline (Fig. 5D) .
In the analysis of effects of baseline ASDAS score on its discriminatory capacity after treatment, ASDAS was again consistently one of the best treatment discriminators in both subgroups (Fig. 5E and 5F ). Effect size was slightly larger in the very high disease activity group compared with the high disease activity group (adjusted effect size 0.97 and 0.84, respectively).
Discussion
In this post hoc analysis of the randomized controlled ASCEND trial, we found that ASDAS was a valid efficacy assessment tool when compared with standard measures of AS assessment, including partial remission and ASAS20. Indeed, in the overall analysis of effect sizes, ASDAS as well as CRP (as a single measure) showed one of the highest treatment discriminatory capacities of the outcome assessments. Both of these disease activity measures included an objective component. Several commonly used subjective measures (e.g. stiffness, back pain) demonstrated similar discriminatory capacity between treatments in the overall analysis of effect sizes, albeit not to the same extent as ASDAS or CRP. Although the latter finding highlights the ongoing importance of subjective measures in the clinical assessment of AS, subjective measures may be made robust by the addition of more objective components such as ASDAS or CRP. Further research is needed to determine if similar results are obtained with other treatments. In addition, ASDAS (along with physician global disease activity) was one of the most sensitive assessments in detecting improvement from baseline in each treatment arm.
Our subgroup analysis revealed greater discriminatory capacity of ASDAS relative to BASDAI in both patients with normal and those with elevated CRP level, but the mean change from baseline improvement in ASDAS and BASDAI was greatest in patients with a high CRP level at Findings are shown for patients with normal (A) and high (B) CRP level at baseline; no peripheral joint arthritis (C) and peripheral joint arthritis (D) at baseline; and high disease activity (E) and very high disease activity (F) at baseline. The width of the 95% CI for ASQoL is attributable to the smaller sample size relative to other endpoints. The CRP subgroups were those with levels within the normal reference range and those with levels above the upper limit of normal. Peripheral joint arthritis at baseline was defined as either swollen joints 51 or tender joints 51. Because 10 patients had no baseline joint assessments, a diagnostic history of peripheral joint arthritis was used. High disease activity was defined as 52.1 ASDAS 43.5, and very high disease activity was defined as ASDAS >3.5. baseline. These data are partly corroborated by results of a recent prospective study of 60 patients who received treatment with an anti-TNF-a inhibitor for 46 weeks, which demonstrated that ASDAS may better reflect the inflammatory disease processes of axial SpA [15] . In this prospective study, high ASDAS at baseline was associated with high levels of inflammatory biomarkers, whereas high BASDAI at baseline was not related to any biomarkers [15] . Major improvement in ASDAS was associated with larger percentage decreases in biomarkers of inflammation, angiogenesis, MMP-3 and increases in aggrecan and OC; however, BASDAI response was associated with larger decreases in CRP and IL-6 [15] . ASDAS was the most capable tool to discriminate between treatments according to ASDAS level of disease activity. ASDAS consistently performed as one of the best measures of treatment discrimination in all different patient subgroup populations. It was also one of the best measurements detecting improvement from baseline for both etanercept and SSZ. No other measurement had this consistency across all analyses. For example, CRP was one of the best treatment discriminators for the overall study population, high baseline CRP population, peripheral joint arthritis population and high as well as very high baseline disease activity; however, this measure performed poorly in the normal baseline CRP population and in the population without peripheral joint arthritis. CRP performed poorly for both treatment groups in detecting improvement from baseline. ASDAS had larger effect sizes in the worst baseline subgroups, such as those with high CRP vs normal CRP, any peripheral joints arthritis vs none, and in very high disease activity vs high disease activity.
Our study was limited by the well-known drawbacks of retrospective analysis as well as by the lack of a placebo arm in the source study. Nevertheless, among the attributes of the study are utilization of prospectively collected data derived from a randomized controlled clinical trial, and the comparison of two commonly used agents (when the study was conducted) in patients with AS and attendant peripheral arthritis (consistent with treatment guidelines of the time) using many different disease assessment tools. In addition, performance of the subgroup analyses was important to confirm the usefulness of ASDAS across patient populations, as both a measure of disease status and response to treatment. One caveat is that the rank order of the assessments may differ somewhat if these analyses were to be validated using data from other studies.
Conclusions
ASDAS, a composite objective and subjective disease measure, is a highly discriminatory tool for the detection of differences between treatments for AS. ASDAS is capable of detecting improvement from baseline in patients with or without an elevated CRP level or peripheral joint arthritis as well as in patients with high or very high disease activity.
Rheumatology key messages
. ASDAS is a new composite clinical tool for assessing patients with AS. . In ASCEND, ASDAS was highly discriminatory in detecting differences between treatments for AS. . In ASCEND, ASDAS detected improvement from baseline in a variety of patient subgroup populations.
